The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients

References

• CoppensMEikelboomJWGustafssonDWeitzJIHirshJTranslational success stories: development of direct thrombin inhibitorsCirc Res2012111792092922982873
   PubMed Web of Science ®Google Scholar
• OlssonSBExecutive Steering Committee of the SPORTIF III InvestigatorsStroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialLancet200336293971691169814643116
   PubMed Web of Science ®Google Scholar
• MohapatraRTranMGoreJMSpencerFAA review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin eraAm Heart J20051501192616084146
   PubMed Web of Science ®Google Scholar
• BatesSMWeitzJIThe mechanism of action of thrombin inhibitorsJ Invasive Cardiol200012Suppl F27F32F
   PubMedGoogle Scholar
• ErikssonBIQuinlanDJEikelboomJWNovel oral factor Xa and thrombin inhibitors in the management of thromboembolismAnnu Rev Med201162415721226611
   PubMed Web of Science ®Google Scholar
• BeckerRCCell-based models of coagulation: a paradigm in evolutionJ Thromb Thrombolysis2005201656816133899
   PubMed Web of Science ®Google Scholar
• WeitzJIHudobaMMasselDMaraganoreJHirshJClot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitorsJ Clin Invest19908623853912384594
   PubMed Web of Science ®Google Scholar
• WeitzJILeslieBHudobaMThrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitorsCirculation19989765445529494024
   PubMed Web of Science ®Google Scholar
• VanasscheTVerhaegenJPeetermansWEInhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulenceJ Thromb Haemost20119122436244622040101
   PubMed Web of Science ®Google Scholar
• XiaoZThérouxPPlatelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitorCirculation19989732512569462526
   PubMed Web of Science ®Google Scholar
• AnsellJWarfarin versus new agents: interpreting the dataHematology Am Soc Hematol Educ Program2010201022122821239798
   PubMedGoogle Scholar
• WrigleyBJLipGYShantsilaENovel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practiceInt J Clin Pract201064783583820584215
   PubMed Web of Science ®Google Scholar
• StangierJClinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilateClin Pharmacokinet200847528529518399711
   PubMed Web of Science ®Google Scholar
• StangierJErikssonBIDahlOEPharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacementJ Clin Pharmacol200545555556315831779
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStähleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol200764329230317506785
   PubMed Web of Science ®Google Scholar
• EisertWGHauelNStangierJWienenWClemensAvan RynJDabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombinArterioscler Thromb Vasc Biol201030101885188920671233
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStähleHMazurDInfluence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre studyClin Pharmacokinet201049425926820214409
   PubMed Web of Science ®Google Scholar
• WannLSCurtisABEllenbogenKA2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesJ Am Coll Cardiol201157111330133721324629
   PubMed Web of Science ®Google Scholar
• BlechSEbnerTLudwig-SchwellingerEStangierJRothWThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humansDrug Metab Dispos200836238639918006647
   PubMed Web of Science ®Google Scholar
• StangierJStähleHRathgenKRothWShakeri-NejadKPharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairmentJ Clin Pharmacol200848121411141918827075
   PubMed Web of Science ®Google Scholar
• NutescuEChuatrisornIHellenbartEDrug and dietary interactions of warfarin and novel oral anticoagulants: an updateJ Thromb Thrombolysis201131332634321359645
   PubMed Web of Science ®Google Scholar
• StangierJStähleHRathgenKFuhrRPharmacokinetics and pharma-codynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjectsClin Pharmacokinet2008471475918076218
   PubMed Web of Science ®Google Scholar
• van RynJStangierJHaertterSDabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activityThromb Haemost201010361116112720352166
   PubMed Web of Science ®Google Scholar
• StangierJFeuringMUsing the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranBlood Coagul Fibrinolysis201223213814322227958
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• SkanesACHealeyJSCairnsJAFocused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm controlCan J Cardiol201228212513622433576
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaRESC Committee for Practice Guidelines-(PG)Document Reviewers 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
   PubMed Web of Science ®Google Scholar
• HartRGDienerHCYangSIntracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialStroke20124361511151722492518
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• EikelboomJWWallentinLConnollySJRisk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialCirculation2011123212363237221576658
   PubMed Web of Science ®Google Scholar
• UchinoKHernandezAVDabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trialsArch Intern Med2012172539740222231617
   PubMed Web of Science ®Google Scholar
• HohnloserSHOldgrenJYangSMyocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialCirculation2012125566967622215856
   PubMed Web of Science ®Google Scholar
• DansALConnollySJWallentinLConcomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trialCirculation2013127563464023271794
   PubMed Web of Science ®Google Scholar
• EikelboomJWWeitzJIAnticoagulation therapy. Dabigatran and risk of myocardial infarctionNat Rev Cardiol20129526026222411291
   PubMed Web of Science ®Google Scholar
• WallentinLYusufSEzekowitzMDRE-LY investigatorsEfficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLancet2010376974597598320801496
   PubMed Web of Science ®Google Scholar
• BeasleyBNUngerEFTempleRAnticoagulant options – why the FDA approved a higher but not a lower dose of dabigatranN Engl J Med2011364191788179021488759
   PubMed Web of Science ®Google Scholar
• DienerHCConnollySJEzekowitzMDRE-LY study groupDabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trialLancet Neurol20109121157116321059484
   PubMed Web of Science ®Google Scholar
• Birman-DeychERadfordMJNilasenaDSGageBFUse and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillationStroke20063741070107416528001
   PubMed Web of Science ®Google Scholar
• RajiMALoweryMLinYLKuoYFBaillargeonJGoodwinJSNational utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D benefciariesAnn Pharmacother2013471354223324508
   PubMed Web of Science ®Google Scholar
• MercaldiCJCiarametaroMHahnBCost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillationStroke201142111211821148442
   PubMed Web of Science ®Google Scholar
• HealeyJSEikelboomJDouketisJRE-LY InvestigatorsPeriprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trialCirculation2012126334334822700854
   PubMed Web of Science ®Google Scholar
• WazniOMBeheirySFahmyTAtrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural periodCirculation2007116222531253417998456
   PubMed Web of Science ®Google Scholar
• WinkleRAMeadRHEngelGKongMHPatrawalaRAThe use of dabigatran immediately after atrial fibrillation ablationJ Cardiovasc Electrophysiol201223326426821955008
   PubMed Web of Science ®Google Scholar
• LakkireddyDReddyYMDi BiaseLFeasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registryJ Am Coll Cardiol201259131168117422305113
   PubMed Web of Science ®Google Scholar
• KaiserDWStreurMMNagarakantiRWhalenSPEllisCRContinuous warfarin versus peri-procedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial futterJ Interv Card Electrophysiol [Epub April 28, 2013]
   Google Scholar
• KimJSSheFJongnarangsinKDabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillationHeart Rhythm201310448348923237911
   PubMed Web of Science ®Google Scholar
• VranckxPVerheugtFWde MaatMPA randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patientsEuro Intervention2013891052106023182947
   PubMedGoogle Scholar
• EzekowitzMDReillyPANehmizGDabigatran with or without concomitant aspirin compared with warfarin alone in patients with non-valvular atrial fibrillation (PETRO Study)Am J Cardiol200710091419142617950801
   PubMed Web of Science ®Google Scholar
• LownBPerlrothMGKaidbeySAbeTHarkenDE“Cardioversion” of atrial fibrillation. A report on the treatment of 65 episodes in 50 patientsN Engl J Med196326932533113931297
   PubMed Web of Science ®Google Scholar
• JensenJBHumphriesJOKouwenhovenWBJudeJRElectroshock for atrial futter and atrial fibrillation. Follow-up studies on 50 patientsJAMA196519411118111845897736
   PubMed Web of Science ®Google Scholar
• BjerkelundCJOrningOMThe efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillationAm J Cardiol19692322082164180019
   PubMed Web of Science ®Google Scholar
• FusterVRydénLECannomDSAmerican College of Cardiology/American Heart Association Task Force on Practice GuidelinesEuropean Society of Cardiology Committee for Practice GuidelinesEuropean Heart Rhythm AssociationHeart Rhythm SocietyACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyCirculation20061147e257e35416908781
   PubMed Web of Science ®Google Scholar
• NagarakantiREzekowitzMDOldgrenJDabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversionCirculation2011123213113621200007
   PubMed Web of Science ®Google Scholar
• Van de WerfFBrueckmannMConnollySJA comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)Am Heart J2012163693193722709744
   PubMed Web of Science ®Google Scholar
• SouthworthMRReichmanMEUngerEFDabigatran and postmarketing reports of bleedingN Engl J Med2013368141272127423484796
   PubMed Web of Science ®Google Scholar
• NagarakantiREllisCRDabigatran in clinical practiceClin Ther201234102051206023031622
   PubMed Web of Science ®Google Scholar
• HylekEMGoASChangYEffect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillationN Engl J Med2003349111019102612968085
   PubMed Web of Science ®Google Scholar